Evoke Pharma, Inc.(EVOK)Earnings, Financials & Key Ratios
EVOK•NASDAQ
$11.00
Price updated Jun 20, 2026
AboutEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Show more
- Revenue$10M+97.8%
- EBITDA$0+100.0%
- Net Income-$5M+31.3%
- EPS (Diluted)-2.81+90.0%
- Gross Margin96.52%+0.4%
- Operating Margin-50.78%+64.6%
- Net Margin-52.22%+65.3%
- ROE-240.09%+76.8%
EVOK Price & Volume
Evoke Pharma, Inc. (EVOK) stock price & volume — 10-year historical chart
Loading chart...
Gimoti Commercial Scaling Faces Persistent Liquidity Constraints
Investment Thesis • Updated 2025Q3
VerdictNegative: The company's persistent cash burn
Growth:Expanding
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and dilution risk
Key Thesis Takeaways
- Evoke Pharma is currently navigating a critical commercialization phase for its Gimoti nasal spray, evidenced by a 61.4% year-over-year revenue growth in 2025Q3.
- While the company demonstrates superior unit economics with a 97.6% gross margin, the path to profitability remains obscured by a $1.2 million net loss in the most recent quarter.
- Investors should monitor the company's ability to manage its $5.1 million debt load against a narrowing cash position of $11.6 million to avoid further dilutive financing.
Verdict Logic
evidenced by a -12.2% free cash flow margin in 2025Q3, combined with an accumulated deficit of $132.8 million, presents significant risks to long-term shareholder value.
EVOK Growth Metrics
Evoke Pharma, Inc. (EVOK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years85.03%
TTM67.4%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.98%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM78.54%
Return on Capital
10 Years-180.96%
5 Years-213.34%
3 Years-167.93%
Last Year-228.28%
Peers Comparison
Key metrics vs top competitors for Evoke Pharma, Inc. (EVOK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.00 | $18.95M | -3.91 | 97.84% | -52.22% | -240.09% | — | |
| $22.41 | $39.12M | -7.65 | 5.05% | -5.83% | -9.12% | — | |
| $2.17 | $17.58M | -1.00 | 1.84% | -60.17% | -148.91% | — | |
| $1.13 | $71.9M | -3.53 | — | — | -929.28% | — | |
| $2.99 | $123.32M | -0.11 | — | — | — | — | |
| $83.28 | $1.89B | 25.08 | 43.78% | 9.71% | 17.32% | — |
Compare EVOK vs Peers
Evoke Pharma, Inc. (EVOK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when EVOK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EVOK Frequently Asked Questions
Evoke Pharma, Inc. (EVOK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Evoke Pharma, Inc.'s revenue?
Evoke Pharma, Inc. (EVOK) reported $14.4M in revenue for fiscal year 2024.
How fast is Evoke Pharma, Inc. growing?
Evoke Pharma, Inc. (EVOK) grew revenue by 97.8% over the past year. This is strong growth.
Is EVOK profitable?
Evoke Pharma, Inc. (EVOK) reported a net loss of $5.2M for fiscal year 2024.
Dividend & Returns
What is EVOK's return on equity?
Evoke Pharma, Inc. (EVOK) has a return on equity (ROE) of -240.1%. Negative ROE indicates the company is unprofitable.
What is Evoke Pharma, Inc.'s free cash flow?
Evoke Pharma, Inc. (EVOK) had negative free cash flow of $3.3M in fiscal year 2024, likely due to heavy capital investments.